EGFR and metastatic colorectal cancer: In a phase III randomized clinical trial on metastatic colorectal cancer, the anti-EGFR monoclonal antibody cetuximab activated tumor-promoting M2 macrophages in the local TME, thus releasing multiple anti-inflammatory factors and pro-tumor mediators, and the infiltration of M2 macrophages was closely associated with poor prognosis [58, 59].